Acute myeloid leukemia (AML) is a biologically heterogeneous hematologic malignancy in which recurrent cytogenetic and molecular abnormalities critically influence diagnostic classification, prognosis, therapeutic allocation, measurable residual disease (MRD) assessment, and relapse biology. Over the last decade, next-...
P. Chiusolo, R. Maggi, Angela Alessi et al.· Mediterranean Journal of Hem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.